Chaudhuri, K. Ray http://orcid.org/0000-0003-2815-0505
Azulay, Jean-Philippe http://orcid.org/0000-0001-6624-3329
Odin, Per
Lindvall, Susanna
Domingos, Josefa http://orcid.org/0000-0001-9390-6183
Alobaidi, Ali http://orcid.org/0000-0002-0720-7894
Kandukuri, Prasanna L. http://orcid.org/0000-0002-3702-4343
Chaudhari, Vivek S. http://orcid.org/0000-0002-5286-9213
Parra, Juan Carlos http://orcid.org/0000-0002-5613-6121
Yamazaki, Toru http://orcid.org/0000-0002-5124-756X
Oddsdottir, Julia
Wright, Jack http://orcid.org/0000-0002-7380-9754
Martinez-Martin, Pablo http://orcid.org/0000-0003-0837-5280
Funding for this research was provided by:
AbbVie
Article History
Accepted: 26 November 2023
First Online: 9 January 2024
Declarations
:
: K. Ray Chaudhuri has received honoraria for lectures from AbbVie, Britannia, UCB, Zambon, Novartis, Boehringer Ingelheim, and Bial; has taken part in advisory boards for and acted as a consultant for AbbVie, UCB , GKC, Bial, Cynapsus, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Therevance, Scion, Britannia, Acadia, and 4D; and has received grants for investigator-initiated research from Britannia Pharmaceuticals, AbbVie, UCB, GKC, and Bial, and academic grants from EU, IMI EU, Horizon 2020, Parkinson’s UK, NIHR, Parkinson’s disease NMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC, and Wellcome Trust. Per Odin has received honoraria for lectures and advice from Britannia, Bial, Ever Pharma, Nordic Infucare, and Zambon, and has received honoraria for lectures and advice as well as research grants from AbbVie. Jean-Philippe Azulay, Susanna Lindvall, and J Josefa Domingos have no conflicts of interest that are directly relevant to the content of this article. Ali Alobaidi, Prasanna L. Kandukuri, Juan Carlos Parra, and Toru Yamazaki are employees of AbbVie and may own stocks/shares in the company. Vivek S. Chaudhari is a former employee of AbbVie Inc., currently employed by EMD Serono, Inc. and may hold AbbVie stock. Julia Oddsdottir is an employee of IQVIA, which received consultancy fees from AbbVie. Jack Wright is an employee of Adelphi Real World, a consulting company that was hired by AbbVie to perform analyses on the Adelphi Disease Specific Program database. Pablo Martinez-Martin has received honoraria from Bial, for participation in a course, and from the International Parkinson and Movement Disorder Society for activities during the International Congress 2023 and for directing the Clinical Outcome Assessment Program.
: Using a checkbox, patients provided informed consent to take part in the survey. Data were collected in such a way that patients and physicians could not be identified directly, and no personally identifiable data were collected. Physician and patient data were pseudo-anonymized. A code was assigned when data were collected. Upon receipt by the study team, data were pseudo-anonymized again to mitigate against tracing them back to the individual. Data were aggregated before being shared with the researchers and/or for publication. The DSP follows all relevant market research guidelines and complies with the Health Insurance Portability and Accountability Act and equivalent EU European Pharmaceutical Marketing Research Association guidelines and because of the nature of the data, the collection and aggregation did not require ethics committee approval. The DSP and all questionnaires therein were granted an exemption following review by the Western Institutional Review Board (Puyallup, WA, USA) on 3 July, 2019 (AG8689).
: Respondents provided informed consent for use of their data; all data were aggregated and de-identified before receipt.
: Not applicable.